About UsNewsShop
Fighting hereditary breast and ovarian cancer
Information & Research
| More


AZD2281 and Carboplatin in Treating Patients With BRCA1/BRCA2-Associated, Hereditary, or Triple Negative Metastatic or Unresectable Breast Cancer or Ovarian Epithelial Cancer

Study identifier: NCT00647062
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Olaparib (AstraZeneca)


  • Documented deleterious BRCA1/BRCA2 germline mutation or BRCAPRO score ≥ 30%
  • Sporadic ovarian serous epithelial cancer with negative family history, BRCAPRO score ≤ 20%, or negative BRCA1/BRCA2 mutation
  • Metastatic or unresectable disease for which standard curative measures do not exist or are no longer effective
  • Measurable and/or evaluable disease
  • At least 6 months since prior platinum drugs
  • Patients with platinum-resistant disease are eligible

Type of study:

Phase I study


Participants receive a combination of olaparib and carboplatin. 

Study site:


National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
Contact: Laura D.Otten, R.N., B.S.N., O.C.N.
Medical Oncology Referral Coordinator 301-451-1228
1-866-611-6310 (Toll Free) ottenl@mail.nih.gov


Page updated 03/26/11

Disclaimer: Health links are made available for educational purposes only. This information should not be interpreted as medical advice. All health information should be discussed with your health care provider. Please read our full disclaimer for more information.

Privacy Policy | Sitemap | Contact Us


This site has been made possible by a generous grant from Morphotek.

Web design by Rareheron Web Design

copyright © FORCE: Facing Our Risk of Cancer Empowered, Inc.  •  info@facingourrisk.org